- Geriatric patients (≥70 years old) given the oral CDK4/6 inhibitor palbociclib for hormone receptor (HR)-positive metastatic breast cancer (mBCa) display no differences in common toxicities or PFS vs younger patients.
Why this matters
- Although >40% of newly diagnosed patients with mBCa are ≥70 years old; geriatric patients are often excluded from clinical trials.
- This is the first cohort study to address the gap, and was conducted in a real-world setting.
- Findings are reassuring, given that palbociclib+aromatase inhibitor is becoming the frontline standard of care for HR+ mBCa.
- Retrospective cohort of 605 patients at MD Anderson Cancer Center with HR+ mBCa; 92 were aged ≥70 years and 160 were aged ≥65 years.
- Funding: National Cancer Institute.
- Patients ≥70 years had more dose reductions (22.8% vs 8.0% of younger patients had 2 dose reductions; P<.0001 and dose delays vs p than younger patients.>
- Patients ≥70 years (vs younger counterparts) had no differences in PFS in multivariate analysis or in common palbociclib toxicities (including neutropenic fever, infections, or hospitalizations because of infections).
- Older patients had a higher comorbidity index, and these common toxicities may be unrelated to those driving palbociclib dose reductions/delays.
- Single-center study.
- Observational design.